Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aracmyn for Black Widow Spider Bite
NCT00247078Phase 2Completed
- Sponsor
- Instituto Bioclon S.A. de C.V.
- Start
- Oct 2005
- Primary completion
- Oct 2006
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in latrodectism comparing Aracmyn with Placebo (2 arms). Primary endpoint: Difference in pain intensity (VAS) at 2 hours. Started Oct 2005; status: completed.
02
Drugs
Antivenin (Latrodectus mactans)
03
Conditions
latrodectism
Beyond the preview
Go deeper on NCT00247078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00247078.